CLSD
NASDAQ
US
Clearside Biomedical, Inc. - Common Stock
$0.30
▲ +$0.03
(+12.84%)
Vol 130K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$4.1M
ROE
-242.7%
Margin
-665.2%
D/E
0.00
Beta
1.67
52W
$0–$17
Wall Street Consensus
8 analysts · Apr 20260
Strong Buy
0
Buy
5
Hold
1
Sell
2
Strong Sell
0.0%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 50.0%
Next Report
May 12, 2026
EPS Estimate: $-0.20
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.20 | — | — |
| Sep 2025 | $-0.54 | $-1.14 | $-0.60 |
| Jun 2025 | $-1.55 | $-0.90 | +$0.65 |
| Mar 2025 | $-1.66 | $-1.65 | +$0.01 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | $1.0M | $306K | $2.3M | $492K | $201K |
| Net Income | -$7.7M | -$7.3M | -$8.2M | -$4.5M | -$6.0M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -242.7% | -242.7% | -242.7% | -242.7% | -242.7% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -913.6% | -818.6% | -665.2% | -665.2% | -665.2% | -665.2% |
| Gross Margin | 100.0% | 89.5% | 90.5% | 90.5% | 90.5% | 90.5% |
| D/E Ratio | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 3.87 | 3.19 | 3.87 | 3.87 | 3.87 | 3.87 |
Key Ratios
ROA (TTM)
-124.2%
P/S (TTM)
0.99
P/B
6.4
EPS (TTM)
$-4.02
CF/Share
$-0.61
Rev Growth 3Y
-61.7%
52W High
$17.10
52W Low
$0.31
$0.31
52-Week Range
$17.10
Financial Health
Free Cash Flow
-$5.5M
Net Debt
-$6.4M
Cash
$6.8M
Total Debt
$446K
As of Sep 30, 2025
How does CLSD compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
CLSD valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
1.0
▼
80%
below
peers
(5.0)
vs Peers
vs Industry
Undervalued
P/B ratio
6.4
▲
200%
above
peers
(2.1)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
CLSD profitability vs Pharmaceuticals peers
ROE
-242.7%
▼
347%
below
peers
(-54.3%)
vs Peers
vs Industry
Weak
Net margin
-665.2%
▼
1304%
below
peers
(-47.4%)
vs Peers
vs Industry
Weak
Gross margin
90.5%
▲
32%
above
peers
(68.3%)
vs Peers
vs Industry
Below avg
ROA
-124.2%
▼
232%
below
peers
(-37.4%)
vs Peers
vs Industry
Weak
CLSD financial health vs Pharmaceuticals peers
D/E ratio
0.0
▼
100%
below
peers
(1.5)
vs Peers
vs Industry
Low debt
Current ratio
3.9
▲
15%
above
peers
(3.4)
vs Peers
vs Industry
In line
Beta
1.7
▲
78%
above
peers
(0.9)
vs Peers
vs Industry
More volatile
CLSD fundamentals radar
CLSD
Peer median
Industry
CLSD profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CLSD vs peers: key metrics
Top Holders
Top 5: 8.45%Vanguard Group Inc
4.24%
$91K
Carmignac Gestion
1.92%
$41K
Geode Capital Management, L…
1.01%
$22K
Blackrock Inc.
0.80%
$17K
Renaissance Technologies, L…
0.48%
$10K
As of Sep 30, 2025
Latest News
No related news yet